Epilepsy is a chronic neurological disorder whose pathophysiology relates to inflammation. The potassium channel Kv1.3 in microglia has been reported as a promising therapeutic target in neurological diseases in which neuroinflammation is involved, such as multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), and middle cerebral artery occlusion/reperfusion (MCAO/R). Currently, little is known about the relationship between Kv1.3 and epilepsy. In this study, we found that Kv1.3 was upregulated in microglia in the KA-induced mouse epilepsy model. Importantly, blocking Kv1.3 with its specific small-molecule blocker 5-(4-phenoxybutoxy)psoralen (PAP-1) reduced seizure severity, prolonged seizure latency, and decreased neuronal loss. Mechanistically, we further confirmed that blockade of Kv1.3 suppressed proinflammatory microglial activation and reduced proinflammatory cytokine production by inhibiting the Ca/NF-κB signaling pathway. These results shed light on the critical function of microglial Kv1.3 in epilepsy and provided a potential therapeutic target.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740890 | PMC |
| http://dx.doi.org/10.3390/ijms232314693 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of tetraethylammonium (TEA) and Tris loading for blocking TRPM7 channels in intact cells.
Front Pharmacol
April 2024
Department of Neuroscience, Cell Biology and Physiology, Boonshoft School of Medicine and College of Science and Mathematics, Wright State University, Dayton, OH, United States.
Tetraethylammonium (TEA), a quaternary ammonium compound, is a well-known blocker of potassium channels belonging to various subfamilies, such as K1-3, K1, 2 and prokaryotic KcsA. In many cases, TEA acts from the extracellular side by open pore blockade. TEA can also block transient receptor potential (TRP) cation channels, such as TRPM7, in a voltage-dependent manner.
View Article and Find Full Text PDFInteraction of the Inhibitory Peptides ShK and HmK with the Voltage-Gated Potassium Channel K1.3: Role of Conformational Dynamics.
J Chem Inf Model
May 2023
Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Peptide toxins that adopt the ShK fold can inhibit the voltage-gated potassium channel K1.3 with IC values in the pM range and are therefore potential leads for drugs targeting autoimmune and neuroinflammatory diseases. Nuclear magnetic resonance (NMR) relaxation measurements and pressure-dependent NMR have shown that, despite being cross-linked by disulfide bonds, ShK itself is flexible in solution.
View Article and Find Full Text PDFPharmacological Screening of Venoms from Five Brazilian Species on Different Ion Channels.
Int J Mol Sci
July 2022
Toxicology and Pharmacology, Campus Gasthuisberg O&N2, University of Leuven (KU Leuven), Herestraat 49, P.O. Box 922, B-3000 Leuven, Belgium.
Article Synopsis
- Coral snake venoms from Brazil, while diverse with 34 known species, have been largely underexplored despite their complex composition and potential medical applications.
- The study utilized the two-microelectrode voltage clamp technique to analyze the venom effects of five different species, revealing that they can inhibit muscle-type and neuronal-type receptors, showcasing various levels of reversibility.
- The findings suggest that the venom's ability to inhibit potassium channels is a key element in their envenomation strategy, though sodium channels were not targeted by the venoms tested.
Microglia-Mediated Inflammation and Neural Stem Cell Differentiation in Alzheimer's Disease: Possible Therapeutic Role of K1.3 Channel Blockade.
Front Cell Neurosci
April 2022
Department of Physiology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain.
Increase of deposits of amyloid β peptides in the extracellular matrix is landmark during Alzheimer's Disease (AD) due to the imbalance in the production vs. clearance. This accumulation of amyloid β deposits triggers microglial activation.
View Article and Find Full Text PDFIdentification of WP1066, an inhibitor of JAK2 and STAT3, as a K 1.3 potassium channel blocker.
Br J Pharmacol
July 2021
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background And Purpose: K 1.3 potassium channels play a predominant role in regulating calcium signalling that is essential for the activation and proliferation of effector memory T (T ) cells. This ion channel has been recognized as a promising therapeutic target against various autoimmune diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!